Cargando…
Metastatic anorectal melanomas – An exploratory retrospective analysis on the benefits of systemic therapy versus best supportive care in a resource-limited setting from India
AIM: Data regarding the optimal management of metastatic anorectal melanoma (mARM) is scarce. The primary aim was to evaluate the potential benefits of systemic therapy in mARM. MATERIALS AND METHODS: This is a retrospective analysis of all mARM who presented between July 2013 and June 2015 at the D...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5763621/ https://www.ncbi.nlm.nih.gov/pubmed/29404289 http://dx.doi.org/10.4103/sajc.sajc_276_16 |
_version_ | 1783291918025752576 |
---|---|
author | Sahu, Arvind Ramaswamy, Anant Singhal, Nitin Doshi, Vipul Mirani, Jimmy Desouza, Ashwin Banavali, Shripad Saklani, Avanish Ostwal, Vikas |
author_facet | Sahu, Arvind Ramaswamy, Anant Singhal, Nitin Doshi, Vipul Mirani, Jimmy Desouza, Ashwin Banavali, Shripad Saklani, Avanish Ostwal, Vikas |
author_sort | Sahu, Arvind |
collection | PubMed |
description | AIM: Data regarding the optimal management of metastatic anorectal melanoma (mARM) is scarce. The primary aim was to evaluate the potential benefits of systemic therapy in mARM. MATERIALS AND METHODS: This is a retrospective analysis of all mARM who presented between July 2013 and June 2015 at the Department of GI Medical Oncology, Tata Memorial Hospital. RESULTS: Of a total of 37 patients, twelve patients were planned for best supportive care (BSC) only while the remaining 25 patients received systemic therapy. The median overall survival (OS) for the whole cohort was 27 weeks. The OS was significantly better in patients who received first-line therapy as compared to those who were offered BSC (median OS: 14 vs. 33 weeks; P = 0.04). Patients with PS of 1 did significantly better than PS of 2 more (OS 70 vs. 17 weeks; P = 0.015). CONCLUSION: mARM should be offered chemotherapy, especially in good performance patients. Paclitaxel/Platinum or Capecitabine/Temozolomide regimens can be considered as the preferred regime in the resource-limited setting where immunotherapy may not be a feasible option. |
format | Online Article Text |
id | pubmed-5763621 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-57636212018-02-05 Metastatic anorectal melanomas – An exploratory retrospective analysis on the benefits of systemic therapy versus best supportive care in a resource-limited setting from India Sahu, Arvind Ramaswamy, Anant Singhal, Nitin Doshi, Vipul Mirani, Jimmy Desouza, Ashwin Banavali, Shripad Saklani, Avanish Ostwal, Vikas South Asian J Cancer ORIGINAL ARTICLE: Gastro-intestinal & Hepatobiliary Cancers AIM: Data regarding the optimal management of metastatic anorectal melanoma (mARM) is scarce. The primary aim was to evaluate the potential benefits of systemic therapy in mARM. MATERIALS AND METHODS: This is a retrospective analysis of all mARM who presented between July 2013 and June 2015 at the Department of GI Medical Oncology, Tata Memorial Hospital. RESULTS: Of a total of 37 patients, twelve patients were planned for best supportive care (BSC) only while the remaining 25 patients received systemic therapy. The median overall survival (OS) for the whole cohort was 27 weeks. The OS was significantly better in patients who received first-line therapy as compared to those who were offered BSC (median OS: 14 vs. 33 weeks; P = 0.04). Patients with PS of 1 did significantly better than PS of 2 more (OS 70 vs. 17 weeks; P = 0.015). CONCLUSION: mARM should be offered chemotherapy, especially in good performance patients. Paclitaxel/Platinum or Capecitabine/Temozolomide regimens can be considered as the preferred regime in the resource-limited setting where immunotherapy may not be a feasible option. Medknow Publications & Media Pvt Ltd 2017 /pmc/articles/PMC5763621/ /pubmed/29404289 http://dx.doi.org/10.4103/sajc.sajc_276_16 Text en Copyright: © 2017 The South Asian Journal of Cancer http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. |
spellingShingle | ORIGINAL ARTICLE: Gastro-intestinal & Hepatobiliary Cancers Sahu, Arvind Ramaswamy, Anant Singhal, Nitin Doshi, Vipul Mirani, Jimmy Desouza, Ashwin Banavali, Shripad Saklani, Avanish Ostwal, Vikas Metastatic anorectal melanomas – An exploratory retrospective analysis on the benefits of systemic therapy versus best supportive care in a resource-limited setting from India |
title | Metastatic anorectal melanomas – An exploratory retrospective analysis on the benefits of systemic therapy versus best supportive care in a resource-limited setting from India |
title_full | Metastatic anorectal melanomas – An exploratory retrospective analysis on the benefits of systemic therapy versus best supportive care in a resource-limited setting from India |
title_fullStr | Metastatic anorectal melanomas – An exploratory retrospective analysis on the benefits of systemic therapy versus best supportive care in a resource-limited setting from India |
title_full_unstemmed | Metastatic anorectal melanomas – An exploratory retrospective analysis on the benefits of systemic therapy versus best supportive care in a resource-limited setting from India |
title_short | Metastatic anorectal melanomas – An exploratory retrospective analysis on the benefits of systemic therapy versus best supportive care in a resource-limited setting from India |
title_sort | metastatic anorectal melanomas – an exploratory retrospective analysis on the benefits of systemic therapy versus best supportive care in a resource-limited setting from india |
topic | ORIGINAL ARTICLE: Gastro-intestinal & Hepatobiliary Cancers |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5763621/ https://www.ncbi.nlm.nih.gov/pubmed/29404289 http://dx.doi.org/10.4103/sajc.sajc_276_16 |
work_keys_str_mv | AT sahuarvind metastaticanorectalmelanomasanexploratoryretrospectiveanalysisonthebenefitsofsystemictherapyversusbestsupportivecareinaresourcelimitedsettingfromindia AT ramaswamyanant metastaticanorectalmelanomasanexploratoryretrospectiveanalysisonthebenefitsofsystemictherapyversusbestsupportivecareinaresourcelimitedsettingfromindia AT singhalnitin metastaticanorectalmelanomasanexploratoryretrospectiveanalysisonthebenefitsofsystemictherapyversusbestsupportivecareinaresourcelimitedsettingfromindia AT doshivipul metastaticanorectalmelanomasanexploratoryretrospectiveanalysisonthebenefitsofsystemictherapyversusbestsupportivecareinaresourcelimitedsettingfromindia AT miranijimmy metastaticanorectalmelanomasanexploratoryretrospectiveanalysisonthebenefitsofsystemictherapyversusbestsupportivecareinaresourcelimitedsettingfromindia AT desouzaashwin metastaticanorectalmelanomasanexploratoryretrospectiveanalysisonthebenefitsofsystemictherapyversusbestsupportivecareinaresourcelimitedsettingfromindia AT banavalishripad metastaticanorectalmelanomasanexploratoryretrospectiveanalysisonthebenefitsofsystemictherapyversusbestsupportivecareinaresourcelimitedsettingfromindia AT saklaniavanish metastaticanorectalmelanomasanexploratoryretrospectiveanalysisonthebenefitsofsystemictherapyversusbestsupportivecareinaresourcelimitedsettingfromindia AT ostwalvikas metastaticanorectalmelanomasanexploratoryretrospectiveanalysisonthebenefitsofsystemictherapyversusbestsupportivecareinaresourcelimitedsettingfromindia |